Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459938 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3S1PR5CACNA1GCACNA1H | |
| SCHEMBL2462250 | 0.81 | S1PR1 (0.42) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL3772219 | 0.78 | S1PR1 (0.47) | S1PR1S1PR3S1PR5CACNA1GCACNA1H | |
| SCHEMBL2454104 | 0.77 | CACNA1G (0.41) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2455974 | 0.76 | S1PR1 (0.48) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2461374 | 0.75 | MAPT (0.42) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2457975 | 0.75 | CACNA1G (0.43) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2463975 | 0.75 | S1PR1 (0.42) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2458999 | 0.74 | S1PR1 (0.52) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2456700 | 0.74 | S1PR1 (0.44) | S1PR1S1PR3S1PR5CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979345-B1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-04 | — | — | EP | claimed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | claimed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | claimed |
| US-8697732-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8178562-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-05-15 | — | — | US | disclosed |
| EP-1979345-B1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005421-A1 | Novel Pyridine Derivatives | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885S1PR5 1144/4885 |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885S1PR5 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.